Hospital to offer new prostate cancer treatment

RFH Healthcare Managing Director Maxwel Okoth addresses a past press breifing. [File, Standard]

RFH Healthcare has announced a medical milestone with the successful administration of Lutetium therapy for the treatment of advanced prostate cancer.

This marks a significant advancement in cancer care, offering hope to patients who previously had to seek specialised treatment abroad.

Lutetium therapy is a targeted radionuclide treatment used primarily for advanced prostate cancer, especially when the disease has become resistant to hormone therapy. By delivering radiation directly to cancer cells while sparing healthy tissue, it offers a more precise and effective option for patients.

“Our commitment is to ensure that patients across Africa can access world-class treatment without having to leave the continent,” said Dr Maxwel Okoth, Managing Director of RFH Healthcare.

Introduction of Lutetium therapy in the region now provides new hope to thousands of patients, who previously had to seek care abroad, often at great financial and emotional cost.

This medical breakthrough is supported by the recent establishment of RFH’s state-of-the-art Diagnostic and Cancer Treatment Center, which boasts some of the most advanced technologies in the region,

Including a SPECT-CT (Single Photon Emission Computed Tomography - CT), PET-CT (Positron Emission Tomography - CT) and Linear Accelerator (LINAC) for high-precision radiotherapy

Keep Reading

“With Lutetium therapy now available locally, we are not only saving lives, but also rewriting the future of cancer care in Africa,” said Dr Okoth.

The new oncology center is part of the RFH Specialist Hospital in Ruai, Nairobi, which serves as the flagship facility within the broader RFH network of 11 branches.

The hospital’s multi-disciplinary approach, ensures that patients receive holistic, dignified, and personalised care from diagnosis to recovery.